Biobeat Secures $50M Series B to Expand U.S. Commercialization of Wearable Blood Pressure Monitoring System
Biobeat Technologies, an innovative med‑tech company developing wearable remote patient monitoring solutions, has completed a $50 million Series B equity financing to accelerate commercialization of its FDA‑cleared, cuff‑less, patch‑worn 24‑hour ambulatory blood pressure monitoring system in the United States.
The funding round was led by new investors Ally Bridge Group, OrbiMed Advisors, and Elevage Medical Technologies, all strategic backers with deep experience in healthcare and med‑tech investing. In addition to the lead firms, the financing included participation from at least one strategic investor, expanding a group of supporters committed to scaling Biobeat’s technology and commercial footprint.
Biobeat’s flagship product is a wearable sensor designed to replace traditional inflatable cuff‑based ambulatory blood pressure monitors. Unlike conventional devices that inflate repeatedly and can disrupt daily activities and sleep, Biobeat’s disposable patch provides continuous blood pressure data over a 24‑hour period without discomfort. After the monitoring period, the patch is disposed of, and comprehensive blood pressure reports are automatically generated and integrated into clinical electronic medical record systems for physician review.
The company, which operates out of both Tel Aviv, Israel, and Boca Raton, Florida, intends to deploy the Series B capital to expand its U.S. commercial operations, including building a robust field sales organization and broadening adoption among clinicians and healthcare institutions. With hypertension affecting more than 100 million adults in the United States alone, Biobeat’s leadership believes that broader use of ambulatory blood pressure monitoring could improve diagnosis, help tailor treatment regimens, and contribute to better long‑term cardiovascular outcomes for patients.
As part of the financing, representatives from the lead investor group joined Biobeat’s board of directors, enhancing alignment between the company’s growth strategy and its investors’ healthcare expertise. Steven Plachtyna from Ally Bridge Group, Dina Chaya from OrbiMed Advisors, and Evan Melrose from Elevage Medical Technologies took board seats, signaling strong strategic backing and collaborative governance moving forward.
Under the leadership of Executive Chairman Raymond W. Cohen and CEO Arik Ben Ishay, Biobeat has positioned itself at the intersection of wearable technology and clinical diagnostics. The company’s patch‑based ambulatory blood pressure monitoring system is among a new generation of digital health tools designed to provide clinicians with richer, around‑the‑clock insights into patients’ vital signs. Biobeat’s broader wearable platform also supports remote monitoring of other critical metrics, helping physicians intervene earlier and tailor care more precisely.
The company’s Series B financing reflects growing investor interest in digital health and remote patient monitoring technologies that enhance clinical decision‑making while improving patient comfort and compliance. Hybrid models that combine wearable hardware with cloud‑connected analytics are increasingly viewed as critical components of modern healthcare delivery, particularly in chronic disease management where continuous data can inform more effective treatment strategies.
Biobeat’s technology has received regulatory recognition, including FDA clearance for its cuff‑less monitoring approach, a milestone that underpins the company’s push into wider clinical use. By enabling clinicians to collect continuous, high‑quality blood pressure data without the inconvenience of traditional cuff‑based systems, the company aims to expand the utilization of ambulatory blood pressure monitoring—which is widely regarded as the clinical gold standard but has historically seen limited adoption due to usability barriers.
With the new capital, Biobeat plans to scale its commercial operations and extend collaborations that integrate its monitoring solutions into broader care ecosystems. The company’s focus on comfort, clinical relevance, and seamless integration with healthcare workflows positions it to contribute to the evolving future of hypertension management and chronic disease monitoring.
As demand for remote and continuous monitoring grows alongside broader healthcare digitization trends, Biobeat’s funding success underscores investor confidence in its technology and strategic direction. The Series B round not only provides resources for expansion but also deepens Biobeat’s ties to seasoned healthcare investors who can support the company through commercialization and scaling.
